Glaukos (NYSE:GKOS) Director Aimee Weisner Sells 15,000 Shares

Glaukos Corporation (NYSE:GKOS) Director Aimee Weisner sold 15,000 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the sale, the director owned 18,806 shares in the company, valued at $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Price Performance

NYSE:GKOS opened at $120.27 on Tuesday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $130.69. The firm has a market cap of $6.91 billion, a price-to-earnings ratio of -36.89 and a beta of 0.70. The company’s 50-day moving average is $115.47 and its two-hundred day moving average is $99.23. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The firm had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. During the same period in the prior year, the firm earned ($0.40) EPS. The business’s quarterly revenue was up 35.6% on a year-over-year basis. Research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on GKOS shares. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC boosted their price objective on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. The Goldman Sachs Group restated a “buy” rating and set a $138.00 price objective on shares of Glaukos in a research note on Friday, January 9th. Finally, Stifel Nicolaus upped their price target on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.69.

Institutional Investors Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UMB Bank n.a. grew its position in Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares in the last quarter. First Horizon Corp lifted its stake in shares of Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 223 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of Glaukos in the fourth quarter valued at approximately $28,000. Larson Financial Group LLC increased its stake in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Finally, REAP Financial Group LLC bought a new stake in Glaukos during the third quarter worth approximately $40,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.